API-Bioxal 44.2 mg/ml Bee-Hive Solution
Oxalic Acid
Last verified
Veterinary medicinal product: bee-hive solution. Distribution category: AVM-GSL (Veterinary Medicines Regulations 2013, Schedule 3). Active substance: Oxalic Acid.1
In short: questions and answers
- Does API-Bioxal 44.2 mg/ml Bee-Hive Solution need a prescription?
- Over the counter. As stated in the registration decision.1
- Which animals is API-Bioxal 44.2 mg/ml Bee-Hive Solution for?
- Honey bees.1
- What is the active substance in API-Bioxal 44.2 mg/ml Bee-Hive Solution?
- Oxalic Acid. ATCvet code: QP53AG03.13
- What is the withdrawal period of API-Bioxal 44.2 mg/ml Bee-Hive Solution according to the leaflet?
- Honey bees, honey: 0 days.3
- Dispensing
- Over the counter1
AVM-GSL: Authorised Veterinary Medicine - General Sale List. No prescription is needed and it may be sold by any retailer.12
Supplied without a prescription. As stated in the registration decision.
- Animal species
- Honey bees1
- Active substance
- Oxalic Acid
- ATCvet code
- QP53AG033
- Manufacturer
- Marketing authorisation holder: Chemicals Laif S.P.A
Withdrawal period
| Animal species | Product | days |
|---|---|---|
| Honey bees | honey | 03 |
Summary of product characteristics
Composition
Each ml contains:
Active substance:
Oxalic acid 44.2 mg
(as oxalic acid dihydrate 62.0 mg)
Excipients:
For the full list of excipients, see section 6.1
6.1 List of excipients
Glycerol
Water, purified.
Pharmaceutical form
Bee-hive solution.
Clear colourless-light yellow liquid.
Pharmacological properties
Pharmacotherapeutic group: Ectoparasiticides for topical use, Incl. insecticides, organic acids, oxalic acid.
ATC Vet Code: QP53AG03.
5.1 Pharmacodynamic properties
Oxalic acid is an Organic acid. Oxalic acid is highly effective against phoretic varroa mites. Studies on the mode of action of oxalic acid have indicated that its low pH is a major contributor to the acaricidal effect. Oxalic acid has been shown to concentrate on mite legs and the edges of the exoskeleton, but none was detected in the alimentary system of mites. Therefore, mites are thought to receive the acid by contact.
5.2 Pharmacokinetic particulars
Oxalic acid, the active ingredient of the product, is a natural honey constituent and its concentration in honey depends on the botanical source. No increase of oxalic acid residues over the natural content of honey is to be expected as a consequence of proper product administration. After product treatments, oxalic acid distributes into the intestine and haemolymph of honeybees where its concentration rises temporarily.
When 4.2% oxalic acid (in 60% sucrose syrup) was administered by trickling, peak contamination of worker bees occurred within 4 days post-treatment, declining to 9% and 2% of the maximum value at 7 and 11 days post-treatment, respectively. Oxalic acid was detected in the alimentary system and haemolymph of bees.
Target species
Honey bees (Apis mellifera)
Indications
Treatment of varroosis caused by Varroa destructor in honey bees (Apis mellifera).
Dosage
In-hive use, the product must be used as follows:
Posology and method of administration by trickling:
The dosage required is 5 ml per seam (gap between top bars of frames) of bees. Maximal dose is 50 ml per hive. Up to two treatments per year (winter and/or spring-summer season in brood-free colonies).
The treatment should be made in a single administration. The product should be administered using a syringe along the length of each seam of bees.
Contraindications
None.
Adverse reactions
Target species: Honey bees (Apis mellifera)
| Frequency | Adverse events |
|---|---|
| Very common (>1 colony/ 10 colonies treated): | Slight agitation (during treatment); Increased adult bee mortality (after treatment) |
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also the last section of the package leaflet for contact details.
Warnings
i). Special precautions for use in animals
Administer the treatment without supers. Avoid disturbance to the hives during the days after the treatment.
ii). Special precautions to be taken by the person administering the veterinary medicinal product to animals
This product is a highly acidic solution that may cause severe irritation to the skin and eyes. Avoid contact with the skin, eyes and mucous membranes. When handling the product wear protective clothing, chemical-resistant gloves, and safety glasses. After application, wash hands with soap and water and thoroughly wash any clothing that comes into contact with the product. In case of accidental spillage onto the skin, wash the affected areas immediately with running water. In case of accidental eye contacts, flush the eyes immediately with clear running water for 10 minutes.
Accidental ingestion may cause severe adverse reactions. Children should not come into contact with this veterinary medicinal product. In case of accidental ingestion, clean mouth with water and drink plenty of water or milk. Do not induce vomiting. Seek medical advice immediately.
Do not eat, drink or smoke while handling the product.
Special precautions for the protection of the environment: Not applicable.
iii). Other precautions
None
Use during pregnancy, lactation or lay
Not applicable.
Interactions
Do not use simultaneously with other acaricides.
Overdose
Significantly higher bee mortality was observed in hives that received by trickling a triple dosages of product. In addition, when overdosed, the over-wintering capacity of colonies was diminished and there may be detrimental effects on colony development in the future.
Special warnings
For greatest efficacy, the product should only be used when the quantity of brood in the colony is non-existent or at its lowest levels. Oxalic acid does not penetrate wax so will not kill mites within capped brood and therefore the presence of brood may noticeably reduce the efficacy of the product. As such, the product should be used in winter or following manipulation of the colony to produce a broodless state in summer (e.g. by queen caging).
With regard to summer treatments following queen caging, highest levels of efficacy were achieved when a caging period of at least 25 days was used, at which point the colonies were completely broodless. Despite proper treatment, seriously damaged colonies may not survive due to the effects of varroa infestation.
All colonies in the same apiary should be treated simultaneously to avoid reinfestations.
Integrated Pest Management Programme
The efficacy may vary between colonies due to the conditions of use (residue presence of brood, temperature, reinfestations etc.). The product should therefore be used as a treatment amongst others within an Integrated Pest Management program, and mite drop regularly monitored.
Withdrawal period
Honey: Zero days
Do not use in colonies with supers or during honey flow.'
Incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Immediate packaging
500 ml bottle: White opaque high-density polyethylene bottles with child – resistant screw cap (HDPE) and tamper-evident seal;
Available in pack sizes of 1 x 500 mL bottle
Storage
Do not refrigerate or freeze.
Store in the original package.
Keep the container tightly closed in order to protect from moisture.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf life after first opening the immediate packaging: 12 months.
Disposal of unused product
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
API-Bioxal should not be allowed to contaminate water courses as this may be dangerous for fish and other aquatic organisms. The product should not be disposed of via wastewater.
Additional information
Vm 23101/5000
9 DATE OF FIRST AUTHORISATION
12 July 2023
10 DATE OF REVISION OF THE TEXT
July 2023
PROHIBITION OF SALE, SUPPLY AND/OR USE
Not applicable.
11 CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS
Veterinary medicinal product not subject to prescription.
Approved 12 July 2023
Registration holder
Chemicals Laif S.P.A
Viale dell'Artigianato 13
35010 Vigonza (PD)
Italy
Regulations
- Veterinary Medicines Regulations 2013 (SI 2013/2033), Schedule 32
Sources
- VMD Product Information Database: API-Bioxal 44.2 mg/ml Bee-Hive Solution, 23101/5000
- The Veterinary Medicines Regulations 2013, Schedule 3 (categories of veterinary medicinal products)
- Summary of Product Characteristics: API-Bioxal 44.2 mg/ml Bee-Hive Solution
Other products with the same active substance
- API-Bioxal 0.71 g/g Bee-hive Powder
- Oxuvar 5.7%, 41.0 mg/ml Concentrate for Solution for Honey Bees
- Varroxal 1 g/g Bee-hive Powder for Honey Bees
All products with this active substance (4)